Q3 2026

• NovaLinko Bio Inc founded; dry-lab validation initiated

Q3 2026

• Dry-lab validation completed for six lead programs

Q4 2026

• Wet-lab studies launched; P2 facility initiated

Q1 2027

• (Upcoming) First in vitro efficacy data expected